Matinas BioPharma Holdings (MTNB) Accumulated Expenses (2013 - 2026)
Matinas BioPharma Holdings (MTNB) reported Accumulated Expenses of $694000.0 for Q1 2026, down 41.14% year-over-year from $1.2 million in Q1 2025, and up 53.54% quarter-over-quarter from $452000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Accumulated Expenses (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has 14 years of Accumulated Expenses data on file, last reported at $694000.0 in Q1 2026.
- Accumulated Expenses for Q1 2026 came in at $694000.0, down 41.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $694000.0 (down 41.14% YoY), and the FY2025 annual result was $452000.0, down 74.96% from the prior year.
- Accumulated Expenses improved to $694000.0 in Q1 2026 per MTNB's latest filing, from $452000.0 in the prior quarter.
- Over five years, Accumulated Expenses peaked at $4.3 million in Q2 2022 and troughed at $452000.0 in Q4 2025.
- A 5-year average of $1.5 million and a median of $1.2 million in 2025 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2024 and 2025: Accumulated Expenses jumped 64.51% in 2024, then sank 74.96% in 2025.
- A 5-year view of Accumulated Expenses shows it stood at $3.1 million in 2022, then tumbled by 53.31% to $1.4 million in 2023, then rose by 24.74% to $1.8 million in 2024, then slumped by 74.96% to $452000.0 in 2025, then soared by 53.54% to $694000.0 in 2026.
- Business Quant data shows MTNB's Accumulated Expenses at $694000.0 in Q1 2026, $452000.0 in Q4 2025, and $564000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Matinas BioPharma Holdings | 4.60 Mn | 2.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 694,000.00 |
| Dec 31, 2025 | 452,000.00 |
| Sep 30, 2025 | 564,000.00 |
| Jun 30, 2025 | 795,000.00 |
| Mar 31, 2025 | 1.18 Mn |
| Dec 31, 2024 | 1.81 Mn |
| Sep 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Mar 31, 2024 | 839,000.00 |
| Dec 31, 2023 | 1.45 Mn |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 1.37 Mn |
| Mar 31, 2023 | 510,000.00 |
| Dec 31, 2022 | 3.10 Mn |
| Sep 30, 2022 | 3.70 Mn |
| Jun 30, 2022 | 4.29 Mn |
| Mar 31, 2022 | 482,000.00 |
| Dec 31, 2021 | 2.85 Mn |
| Sep 30, 2021 | 2.89 Mn |
| Jun 30, 2021 | 2.76 Mn |